TMPRSS2 and prostate carcinoma: The unfavorable clinical outcome observed in these patients seems to be strongly influenced by the androgen receptor signaling, a hallmark of prostate cancer, as androgens enhance the expression of the type II protease, TMPRSS2, and suppress the innate and adaptive immune responses [1,33,34].